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G11778A in the subunit ND4 gene of NADH dehydrogenase complex is the most common primary mutation found in Leber's hereditary optic
neuropathy (LHON) patients. The NDI1 gene, which encodes the internal NADH–quinone oxidoreductase in Saccharomyces cerevisiae, was
introduced into the nuclear genome of a mitochondrial defective human cell line, Le1.3.1, carrying the G11778A mutation. In transformant cell
lines, LeNDI1-1 and -2, total and complex I-dependent respiration were fully restored and largely resistant to complex I inhibitor, rotenone,
indicating a dominant role of NDI1 in the transfer of electrons in the host cells. Whereas the original mutant Le1.3.1 cell grows poorly in medium
containing galactose, the transformants have a fully restored growth capacity in galactose medium, although the ATP production was not totally
recovered. Furthermore, the increased oxidative stress in the cells carrying the G11778A mutation was alleviated in transformants, demonstrated
by a decreased reactive oxygen species (ROS) level. Finally, transformants were also shown to be desensitized to induction to apoptosis and also
exhibit greater resistance to paraquat-induced cell death. It is concluded that the yeast NDI1 enzyme can improve the oxidative phosphorylation
capacity in cells carrying the G11778A mutation and protect the cells from oxidative stress and cell death.
© 2007 Elsevier B.V. All rights reserved.Keywords: Mitochondrial; Complex I; LHON; NDI1; Oxidative stress; Apoptosis1. Introduction
The mitochondrial respiratory NADH–ubiquinone oxidore-
ductase (complex I) is the major entry point for electrons into the
electron transport chain. It is embedded in the inner membrane of
mitochondria and is capable of dehydrogenating NADH and
shuttling electrons to ubiquinone in a rotenone-sensitive pathway
[1]. The mammalian complex I consists of 46 subunits [2,3], and
seven of them are encoded by mitochondrial genes [4,5].
Complex I deficiency has been associated with various human
diseases including some neurodegenerative disorders [6]. In
particular, mutations in mitochondrial DNA (mtDNA)-encoded
genes have been identified as the primary genetic cause for
Leber's hereditary optical neuropathy (LHON) [7].
LHON, characterized by acute or subacute bilateral visual
loss [8], was one of first human diseases linked to mtDNA⁎ Corresponding author. Tel.: +1 210 567 0561; fax: +1 210 567 3803.
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doi:10.1016/j.bbadis.2007.01.009mutations. First described last century [9], LHON was found to
be inherited only through maternal transmission [10,11].
However, it was not until 1988 that Wallace and colleagues
identified a point mutation at mitochondrial genome position
11778 in complex I subunit ND4 gene from 11 families with
LHON from Finland and the USA [12]. Subsequent studies
have identified two more primary mutations at position 3460 in
ND1 and position 14484 in ND6 genes [13–15]. These three
mutations account for more than 90% of all LHON cases
[16,17].
The G11778A mutation is responsible for more than half of
LHON cases reported so far in various areas in the world [8,18].
This G to A transition changes conserved arginine to histidine in
the ND4 subunit. Analysis in the muscle biopsy and immorta-
lized lymphoblasts derived from LHON patients carrying the
G11778Amutation revealed a reduction in the complex I-specific
activity [19]. Hofhaus et al. further reported that the defect in
complex I function was transferred along with the mtDNA as the
human cell line transformed with mitochondria from the LHON
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decrease in complex I-dependent respiration and growth capacity
in galactose medium [20].
In contrast to mammalian cells, Saccharomyces cerevisiae
lack complex I. Instead they have a nucleus-encoding NDI1
gene [21–23]. Like complex I, the yeast NDI1 enzyme is the
main entry point into the respiratory chain [23]. NDI1 has been
shown to be active in bacteria [24], Chinese hamster [25] and
human cells [26,27]. The yeast enzyme was also found coupled
to the downstream portion of host respiratory chain. It was
further shown to restore the oxidative phosphorylation capacity
in a human cell deficient in the assembly of complex I [27].
Because most of the pathogenic mtDNA mutations asso-
ciated with inherited mitochondrial diseases are mild missense
mutations, it is important to investigate the behavior of the yeast
NDI1 enzyme in human cells carrying a pathogenic mutation
where complex I is still intact and partially active. Although
complex I-type enzymes and NDI1-type enzymes coexist in the
mitochondria of some bacteria, plants, and fungus [25,27], it is
significant to study the potential interaction between these two
enzymes in the human background if NDI1 is to be considered a
potential gene therapeutic tool. In the present study, the NDI1
gene was introduced into Le1.3.1 cell, a human cell line
carrying the G11778A mutation derived from a LHON patient.
We found that NDI1 protein improved the oxidative phosphor-
ylation capacity of the host cells and at the same time, protected
the cells against the oxidative stress and cell death.2. Materials and methods
2.1. Cell lines and media
143B (ATCC CRL 8303) is a human osteosarcoma-derived cell line. Le1.3.1
was obtained by transferring mitochondria from cultures of skin fibroblast
established from a LHON patient into a mtDNA-less line ρ°206 derived from
143B cell [20]. All the cell lines used in the present work were grown as
monolayer in Dulbecco's modified Eagle's medium (DMEM) supplemented
with 10% fetal bovine serum (FBS).
2.2. NDI1 transfection
The construction of the NDI1 expression vector pHook (NDI1) was
described previously [25]. Le1.3.1 cells were transfected with pHook (NDI1) by
the calcium-phosphate precipitation method [28] and lipofectamine 2000 kit
(Invitrogen). The transfectant cell lines, including LeNDI1-1 (by calcium-
phosphate precipitation) and -2 (by lipofectamine), were isolated by selection in
the DMEM with 10% FBS and 0.4 mg/ml active G418 (geneticin) for 2 weeks,
and then were maintained at 0.1 mg/ml G418. As the transfection control lines,
LeVec-1 and -2 cells were generated by introducing pHook 1into Le1.3.1. cells
with lipofectamine. All the transfectants were derived from single cells.
2.3. NDI1 gene and mRNA detection by PCR amplification
The presence of the NDI1 gene in the transfectant cell lines was analyzed by
polyacrylamide gel electrophoresis after PCR amplification of total cell DNA
[27]. The PCR reactions were carried out by using primers NDI1-For,
AGCACAGCGACAAACCAAAC, and NDI1-Rev, TCAGGTTGGTA-
TAGCTGGCT, to amplify the NDI1 gene. Another set of primers was used for
PCR amplification of the mitochondrial ND4 gene as a control: ND4-For,
TGCCCAAGAACTATCAAACTCC, and ND4-Rev, GGTTTTGGATGA-
GAATGGCTG. PCR was first carried out at 94 °C for 1 min, 50 °C for 1 min,and 72 °C for 1 min. The first 5 cycles were with NDI1 primer set only, and then
ND4 primer set was added for another 30 cycles. Total RNA was isolated by
RNAzol B procedure (Tel-Test, Inc., Friendswood, TX). RNA extracted from
5×106 cells was treated with 10 U of RNase-free RQ DNase (Promega) at 37 °C
for 30 min. After phenol/chloroform/isoamyl alcohol extraction and ethanol
precipitation, the reverse transcription reactions were carried out as previously
described [29]. PCR amplification was performed using the same conditions as
for DNA analysis, and the PCR products were analyzed by polyacrylamide gel
electrophoresis.
2.4. LHON mutation detection
The G11778A point mutation was detected by digestion with a restriction
endonuclease, MaeIII (RocheMolecular Biochemicals, Germany) because the G
to A transition at position 11778 creates a Mae III site. Genomic DNA extracted
from 143B, Le1.3.1 and LeNDI1-1 and -2 cells were subjected to PCR
amplification of a portion of ND4 gene using the ND4-4For, TGCCCAA-
GAACTATCAAACT, and ND4-6Rev, TAAGGGGTCGTAAGCCTCTG, as
primers. PCR was carried out at 94 °C for 30 s, 58 °C for 45 s, and 72 °C for
1 min for 35 cycles. The PCR product was purified with the QIAEX II gel
extraction kit (QIAGEN, CA). The extracted DNAwas then digested by MaeIII
at 55 °C for 4 h. The presence or absence of the G11778Amutation was revealed
by analysis of the electrophoretic patterns in an 8% acrylamide gel.
2.5. O2 consumption measurement
As described previously [30], determination of the O2 consumption rate in
intact cells was carried out with 5×106 cells in Tris-based, Mg2+, Ca 2+-
deficient (TD) buffer. FCCP (carbonylcyanide p-(trifluoromethoxy) phenylhy-
drazone), 1 μM, was added to uncouple mitochondrial respiration. For
measurements of O2 consumption rate in digitonin-permeabilized cells, about
5×106 cells were resuspended in respiration buffer (20 mM HEPES, pH7.1,
250 mM sucrose, 2 mM Kpi, 10 mM MgCl2, and 1.0 mM ADP). The
measurements were carried out in two chambers of an YSI Model 5300
Biological Oxygen monitor. The substrate concentrations were as follows:
malate, glutamate, succinate, and glycerol-3-phosphate (G-3-P), 5 mM;
ascorbate, 10 mM; N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD),
0.2 mM; rotenone, 100 nM; flavone, 0.5 mM; antimycin A, 20 nM.
2.6. Mitochondrial respiratory complexes enzymatic activities
Submitochondrial fractions were obtained by freeze-thawing of isolated
mitochondria in hypotonic buffer (25 mM potassium phosphate, pH7.2 and
5 mM MgCl2) [31]. The methods to measure the complexes activities were
based on those described by Birch-Machin and Turnbull [32]. In particular, the
activity of NADH:ubiquinone oxidoreductase (complex I) was assayed with
0.13 mM NADH and 65 μM decylubiquinone following the decrease in
absorbance due to the oxidation of NADH at 340 nm (ε=6.22×103 M−1 cm−1),
in the presence of 2 mMKCN and 2 μg/ml antimycin A to block complex IVand
III activities, respectively. Enzyme activities were normalized to the protein
amount. For complex III and IV activity assay, submitochondrial fractions were
solubilized with dodecyl maltoside. Complex III activity was measured by
reduction of cytochrome c (III) at 550 nm (ε=21 mM−1 cm−1) by using D-
ubiquinol-2 as an electron donor at 25 °C. Complex IVactivity was measured by
oxidation of cytochrome c (II) at 550 nm (25 °C). All measurements were
performed in triplicate. The protein extracts were quantified with Bradford
method (Bio-rad, Hercules, CA).
2.7. Blue Native Gel electrophoresis
Mitochondria were isolated as previously described [30]. Blue Native PAGE
(BN-PAGE) [33,34] was used for the separation of respiratory complexes on 4–
13% polyacrylamide gradient gels. 50 μg of mitochondrial proteins was loaded
on a minigel of 1.5×70×82 mm (Bio-Rad). The protein complexes were
detected by Western blot and immunodetection with antibodies MS111, MS204,
MS304, MS404, and MS507 for complexes I, II, III, IV, and V respectively. All
the antibodies are from Mitosciences Inc.
Fig. 1. Detection of the NDI1 gene and mRNA in transfectant cells. (A) PCR
amplification was carried out with total cell DNA using two sets of primers
specific for the human mitochondrial ND4 gene and the yeast NDI1 gene. The
products were analyzed by 1% agarose gel electrophoresis. (B) Total RNA from
various cells was subjected to RT-PCR, using the same primers employed in the
DNA analysis, and the products were analyzed by 1% agarose gel
electrophoresis.
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ATP measurements were carried out based on the procedure previously
described by Manfredi et al. [35]. For luciferase assays, aliquots of 1×106 cells
were incubated in DMEM containing the following combinations of substrates
and inhibitors: glucose (4.5 mg/ml) plus 110 mg/l pyruvate; glucose plus 15 μg/
ml the ATP synthase inhibitor oligomycin. Cells were placed in noncoated 24-
well plastic plates and incubated with gentle rocking (to prevent cell attachment)
for an hour at 37 °C. Cells were then collected by centrifugation, and
resuspended in 100 μl buffer containing 25 mM Tris, pH 7.4 and 150 mM
EDTA. The above solution was boiled at 100 °C for 5 min and centrifuged. The
luciferrin–luciferase mixture (Invitrogen) was added to the cell suspension (final
concentration, 2 mM), and light emission was measured in a Synergy™ HT
Multi-Detection Microplate Reader (Bio-Tek Instruments Inc., Winooski, VT).
A standard ATP/luminescence curve was constructed by measuring lumines-
cence derived from ATP solutions containing 0, 0.001, 0.01, 0.1, 1, and 10 μM
ATP in double distilled water and luciferrin–luciferase mixture.
2.9. Growth measurement
Multiple identical samples of 5×103 cells were plated on 6-well plates in
5 ml of medium and cells were cultured at 37 °C for 24 h. The medium was
changed the next day with appropriate media (glucose, DMEM which contain
4.5 mg glucose/ml and 0.11 mg of pyruvate/l or galactose, DMEM lacking
glucose and containing 0.9 mg of galactose/ml and 0.5 mg of pyruvate/l, both
supplemented with 10% dialyzed FBS). Trypan blue exclusion method was then
used to count cell numbers. Cells were counted on a daily basis for 7 days.
2.10. ROS analysis
ROS generation was detected by both 6-carboxy-2′,7′-dichlorofluorescin
diacetate (carboxy-H2DCFDA) and Mitosox Red reagent (both from Invitro-
gen). For carboxy-H2DCFDA assay, cells were harvested and counted by trypan
blue exclusion, and then about 1×104 cells were resuspended with HBSS buffer
and incubated with 1 μM carboxy-H2DCFDA in the loading medium (125 mM
KCl, 10 mM HEPES, 5 mMMgCl2, and 2 mM K2HPO4, pH 7.4) in 5% CO2 at
37 °C for 30 min. After carboxy-H2DCFDAwas removed, the cells were washed
and incubated with HBSS buffer and the fluorescence was measured and
recorded. Carboxy-H2DCFDA-loaded cells were placed in a Perkin Elmer
1000 multiwell fluorescence plate with temperature maintained at 37 °C.
The excitation filter was set at 485±10 nm and the emission filter was set at
530±12.5 nm. The fluorescence from each well was captured, digitized, and
stored on a computer using Cytofluor (Version 2.0, Perkin Elmer). Data
points were taken every 1 min for 60 min and the data were exported to
Excel spreadsheet software for analysis.
Superoxide measurements were carried out with Mitosox assay [36]. About
5×105 cells were resuspended with HBSS buffer and then incubated with
100 nMMitosox (Ex 492 nm and Em 595 nm) in loading medium with 5% CO2
at 37 °C for 10 min. Cells were then washed, and the fluorescence was measured
and recorded in a Perkin Elmer 1000 multiwell fluorescence plate with
temperature maintained at 37 °C.
2.11. Apoptosis assay
To evaluate apoptosis, cells were first grown on the cover glass in 6-well
plates and treated with 500 nM staurosporine for 6 h or 250 μM paraquat for
48 h. Cells were then washed three times with PBS and fixed with 70% ethanol.
Fixed cells were washed again with PBS and stained with 4,6-diamidino-2-
phenylindole (DAPI, 1 μg/ml, Sigma) for 30 min. The number of DAPI stained
nuclei was determined by fluorescence microscopy (Zeiss-Axioplan, Oberko-
chen, Germany) using a UV filter (365/420 nm). Apoptotic cells were
morphologically defined by cytoplasmic and nuclear shrinkage, and chromatin
condensation or fragmentation. All of experiments were carried out on cells with
less than 80% of confluence. To quantify the percentage of apoptotic cells, 4–5
different fields were viewed and at least 1000 cells were observed.
TUNEL assay was performed by following Promega protocol. Cells were
first fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100, and then reacted with rTdT(terminal deoxyribonucleotidyl transferase)
enzyme for 60 min at 37 °C. After incubation with streptoavidin HRP for
30 min, labeled nick ends of DNA strands were visualized with DAB method.
To quantify the percentage of apoptotic cells, 3 different fields were viewed and
over 100 cells each time were observed.
Caspase-Glo 3/7 activity assay: 2×104 cells were grown in 96-well plates
and subsequently treated with 500 nM staurosporine and 250 μM paraquat
respectively. After the treatment, caspase-Glo 3/7 reagent (Promega) was added
and then incubated for 1 h. The luminescence (relative light unit, RLU)
measured by a Synergy™ HT Multi-Detection Microplate Reader (Bio-Tek
Instruments Inc., Winooski, VT).
2.12. Statistical analysis
P, probability, values were calculated by using the ANOVA test contained in
the Minitab program.3. Results
3.1. Transfection of human cells carrying a G11778A mutation
with yeast NDI1 gene
Le1.3.1 is a human cell line carrying the homoplasmic
G11778A mutation in 143B nuclear background [20]. To
introduce NDI1 gene to cells with LHON mutation, Le1.3.1
cells were transfected with the plasmid pHook (NDI1). 48
Transfectants were isolated by resistance to 0.4 mg/ml G418,
and 16 were picked to check if the transfection was successful.
Among 16 clones, 10 were confirmed to carry the NDI1 gene,
LeNDI1-1 and -2 were selected for further analysis. Two
transfection control lines, LeVec-1 and -2, were generated by
introducing pHook-2 vector without NDI1 gene into Le1.3.1
cells. The success of the transfection was verified by PCR
amplification. As shown in Fig. 1A, a NDI1 gene fragment was
detected in LeNDI1-1 and -2 cells. The successful expression of
NDI1 gene was confirmed by detection of NDI1 mRNA by
reverse transcription-PCR (RT-PCR) (Fig. 1B). The results also
showed that LeNDI1-1 had a higher NDI1 gene copy and
exhibited a higher NDI1 mRNA level. The reason why DNA
and RNA levels are not proportional is probably because that
not all the trans-genes are transcribed, and that are more likely
to happen with transfectant high copy number transgene
(LeNDI1-1).
Fig. 3. Respiration measurements in 143B, Le1.3.1, and LeNDI1-1, -2 cells. (A)
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LeNDI1-1 and-2 cells, do carry the G11778A mutation, a
portion of ND4 gene was PCR amplified then digested with a
restriction enzyme MaeIII which recognizes GTNAC. The G to
A transition at 11778 changes the original GTCGC to GTCAC
and creates a new Mae III site. As shown in Fig. 2, the 896 bp
portion of ND4 gene in control 143B cells contains 3 MaeIII
sites thus yielded 4 bands with the sizes of 346, 255, 238 and
57 bp (not shown in the picture) after digestion. While in
Le1.3.1 and both NDI1 transfectant cells, the 255 bp fragment
was further cut into two smaller bands at 131 and 124 bp. These
results indicated that both the NDI1 transfectants still carried the
homoplasmic mutation at 11778 site.
3.2. Respiration properties in the NDI1 transformants
To evaluate the activity of the yeast NDI1 gene in human
cells carrying the mtDNA G11778A mutation, the respiration
properties of the control 143B, the mutant Le1.3.1, and the
NDI1 transformants, LeNDI1-1 and -2 cell lines were
investigated in detail. First, we measured the endogenous
respiration activities of intact 143B, Le1.3.1, LeNDI1-1 and -2
cells. As shown in Fig. 3A, total respiration in NDI1
transformants was fully restored. The respiration rates in
LeNDI1-1 and -2 cells increased by 34.4 (p<0.01) and 46.6%
(p<0.05) compared with the parental Le1.3.1 cells. In the
presence of the chemical uncoupler FCCP that can completely
uncouple mitochondria and raise the respiratory capacity to a
maximal level, oxygen consumption in LeNDI1-1 and -2 cells
was also totally restored (Fig. 3A).
To further exanimate the respiration activities of each
complex in the NDI1 transformed cell, the substrate-dependent
respiration was analyzed on digitonin-permeabilized cells. The
malate/glutamate-driven respiration which reflects the rate-
limiting activity of complex I, the succinate/glycerol-3-
phosphate-driven respiration which reflects the rate-limiting
activity of complex III (ubiquinone–cytochrome c oxidoreduc-
tase) and ascorbate/TMPD-dependent respiration which reflects
the activity of complex IV (cytochrome c oxidase), were
measured. As shown in Fig. 3B, the most significant feature in
LeNDI1-1 and -2 cell lines was that the complex I-dependentFig. 2. Detection of mtDNA G11778A mutation in Le1.3.1 and LeNDI1-1, -2
cells. The G to A transition at position 11778 creates a MaeIII restriction site.
The 896 bp portion of wild-type ND4 gene amplified by PCR (A) contains three
MaeIII sites and will yield bands at 346, 255 and 238 bp after digestion (B).
With the mutant mtDNA, the 255 bp fragment will be further cut into two
smaller bands at 131 and 124 bp. The MaeIII digestion products were separated
by electrophoresis on an 8% polyacrylamide gel.
Endogenous respiration measured in intact cells and after treatment with
uncoupler FCCP. (B) The complex-dependent activities of respiration in
permeabilized cells driven by glutamate/malate (G/M), glycerol-3-phosphate/
succinate (G-3-P/S), and ascorbate/TMPD (A/TMPD). (C) The resistance to
respiration inhibitors rotenone and flavone to complex I-dependent respiration,
antimycin A to complex III-dependent respiration, in permeabilized cells.respiration was 48% (p<0.01) and 39.2% (p<0.005) higher,
respectively, than the level of the mutant Le1.3.1 cells.
To distinguish the NADH dehydrogenase activity of the
human complex I and of the yeast NDI1 enzyme, the difference
in sensitivity to the respiratory inhibitor rotenone [23] was
utilized. As shown in Fig. 3C, respiration in 143B and Le1.3.1
cells was extensively inhibited by 100 nM of complex I
inhibitor, rotenone, while the respiration in LeNDI1-1 and -2
cells was largely resistant to rotenone but mostly inhibited by
Fig. 4. Respiratory complexes assembly analysis. Mitochondria were extracted
and protein complexes were separated on a 4–13% blue native polyacrylamide
gel. Complexes I, II, III, IVand V were identified by Western blot with antibody
against NDUFA9, SDHA, complex III-core 2, complex IV-subunit I and
complex V-α subunit respectively.
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suggested that NDI1 was predominantly utilized while coexist-
ing with a defective complex I. On the other hand, as in 143B
and the parental Le1.3.1 cells, the respiration of LeNDI1-1 and
-2 cells was totally sensitive to complex III inhibitor, antimycin
A, indicating that NDI1 has integrated into the downstream
portion of human respiratory chain (Fig. 3C).
3.3. Mitochondrial respiratory chain enzyme activities
To complement the respiratory measurement, biochemical
assays on the activities of complexes I, III and IV were also
carried out. Mitochondrial membranes were partially purified
from isolated mitochondria [37]. Complex I (NADH–ubiqui-
none oxidoreductase) activity was determined by following the
oxidation of NADH using as electron acceptor DB, which is a
soluble analogue of the endogenous acceptor, ubiquinone [32].
Complex III (ubiquinone–cytochrome c oxidoreductase) activ-
ity was measured by following the reduction of cytochrome c
(III) using D-ubiquinol-2 as the electron donor. Complex IV
(cytochrome c oxidase)-specific activity was measured by
monitoring the oxidation of cytochrome c (II). The enzymatic
activities of 2 transfection control lines, LeVec-1 and -2 were
also measured. As shown in Table 1, while complex I activity of
Le 1.3.1 cells was significantly lower (74%, p<0.005) than the
control, it was shown to increase by 77% (p<0.01) in NDI1
transfected cells compared with the parental Le1.3.1 cells. On
the other hand, we also observed a decrease in complex III
activity (16%, p<0.05) in NDI1 transformants, and no
significant changes were observed in complex IV activity.
3.4. Complex I assembly analysis
The significant resistance of respiration to rotenone in
LeNDI1-1 and -2 cells suggested that complex I was bypassed
largely in electron transfer when it coexisted with NDI1
enzyme. To determine if complex I is still intact in the NDI1
transformed cells, blue native gel electrophoresis (BN-PAGE), a
useful method for isolating intact membrane-bound protein
complexes and for investigating the integrity of mitochondrial
respiratory complexes [38], was carried out. Mitochondrial
samples electrophoresed by using the BN-PAGE system were
subjected to immunoblot analysis for all oxidative phosphor-
ylative complexes. Interestingly, as shown in Fig. 4, there was
an increase in the amount of complex I in NDI1 transformants
by 14–29%, indicating that complex I was still stable.Table 1
Enzymatic assay
Control LHON
143B Le1.3.1 LeNDI1-1
Complex I 0.11±0.0116 0.03±0.0047** 0.12±0.011
Complex III 0.36±0.0096 0.34±0.0063 0.29±0.008
Complex IV 0.11±0.0165 0.11±0.0120 0.13±0.028
Enzyme activities are expressed in nmol min−1 (mg protein)−1. Values shown are th
Statistical significance: *p<0.05, **p<0.01, and ***p<0.005 by the ANOVA test.3.5. ATP synthesis
One major difference between complex I and NDI1 is that
NDI1 lacks the proton pumping ability. It is thus interesting to
check the ATP production in NDI1 transformants. Total ATP
level was measured by luminometry in boiled cells. Compared
with Le1.3.1 cells, we found that the ATP contents increased by
72% (p<0.00005) and 104% (p<0.001) in LeNDI1-1 and -2
cells (Fig. 5). We further investigated the mitochondrial
oxidative phosphorylation contribution to ATP production
with the addition of 15 μg/ml of oligomycin, an ATP synthase
or complex V inhibitor. As shown in Fig. 5, the oligomycin-
sensitive ATP level in LeNDI1-1 and -2 cells increased by 121
and 140%, indicating the recovery was mitochondrial.
3.6. Growth capacity in galactose medium
Mitochondrial oxidative phosphorylation is the major source
for ATP production, while glycolysis is an alternative pathway to
generate ATP. In mammalian cells, galactose cannot be utilized
efficiently in the glycolytic pathway. Consequently, in medium
containing galactose instead of glucose, the cells are forced to
depend predominantly on mitochondrial oxidative phosphoryla-
tion as the source of energy supplies. As shown in Fig. 6, all cells
grew well in the regular glucose medium. However, in the
galactose medium, the wild-type 143B cells still grew well, with
the doubling time at 19.8 h; the mutant Le1.3.1 cells grew ratherLeNDI1-2 LeVec-1 LeVec-2
6*** 0.12±0.0167** 0.02±0.0028 0.05±0.0206
0* 0.29±0.0071* 0.31±0.0035 0.44±0.0364
5 0.10±0.0137 0.21±0.0152 0.12±0.0207
e mean±SEM of 3 independent experiments.
Fig. 5. ATP content analysis. The total cellular ATP contents in 143B, Le1.3.1,
and LeNDI1-1, -2 cells were measured in 1×106 cells with a luciferase detection
kit. The oligomycin-resistant ATP contents (Oligomycin-R) were determined
after cells were incubated with oligomycin, an inhibitor of oxidative phospho-
rylation, for 1 h at 37 °C at the concentration of 15 μg/ml. The oligomycin-
sensitive ATP production (Oligomycin-S) was calculated by subtracting of
oligomycin-sensitive portion from the total ATP content. Four measurements
were carried out, and the error bars indicate 2 times of the standard errors of the
mean.
Fig. 6. Growth capacity of 143B, Le1.3.1, and LeNDI1-1, -2 cells in glucose and
galactose-containing DMEM. Cells were plated on multiple 6-well plates at
5×103 per well and counted on a daily basis for 7 days in glucose (A) and
galactose (B) media.
538 J.S. Park et al. / Biochimica et Biophysica Acta 1772 (2007) 533–542poorly with the doubling time at 27.7 h; the growth capacity in
galactose medium was again totally recovered in LeNDI1-1 and
-2 cells with the doubling time at 19.1 and 19 h.
3.7. ROS generation and oxidative stress in the NDI1
transformants
Oxidative stress has been suggested as a pathogenic
mechanism for mitochondrial disease since mitochondria are
the major source for ROS [39,40]. We first analyzed the cellular
ROS level detected by carboxy-H2DCFDA [41]. Significant
increase of ROS production (57%, p<0.005) was observed in
Le1.3.1 cell compared with 143B cells (Fig. 7A). More
importantly, in LeNDI1-1 and -2 cells where NDI1 was
introduced into the Le1.3.1 background, ROS level was
considerably decreased (about 30%, p<0.01).
To verify this result, we used a mitochondria-specific dye
Mitosox which recognized mitochondrial superoxide radicals.
Again, a substantial decrease was recorded in LeNDI1-1 and -2
cells (about 40%, p<0.001) (Fig. 7B).
3.8. Sensitivity to cell death
It has been suggested that retinal ganglion cells are lost by an
apoptotic pathway in LHON patients [42]. We investigated the
apoptotic features in our cells. We first analyzed the apoptoticFig. 7. Measurement of ROS in 143B, Le1.3.1, and LeNDI1-1, -2 cells. ROS
were measured with two different methods. (A) Cells were harvested and
suspended in a loading medium contained with 1 mM carboxy-H2-DCFDA. (B)
Cells were labeled with 100 nM Mitosox Red reagent. Values shown are the
mean±SEM of 3 independent experiments.
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the condensed chromatin gathering at the periphery of the
nuclear membrane or a total fragmented morphology of nuclear
bodies under the microscope. Cells were incubated with 500 nM
staurosporine, a protein kinase inhibitor which is often used as
an inducer of apoptosis, for 6 h, and then stained with DAPI
which formed fluorescent complexes with double-stranded
DNA. As shown in Fig. 8A, more Le1.3.1 cells which carried
G11778A mutation were apoptotic (24%, p<0.005) compared
with the control 143B cells (5%), while less LeNDI1-1 and -2Fig. 8. Apoptosis assay. Percent of apoptotic cell numbers of 143B, Le1.3.1, and Le
250 μM paraquat (B). The apoptotic cells were defined by round and/or shrunken nuc
LeNDI1-1, -2 cells treated with 500 nM staurosporine (C) and 250 mM of paraqua
TUNEL assay kit from Promega. Activities of caspase 3/7 were measured with cas
250 μM paraquat (F) three independent measurements for each assay were carried ocells exhibited such feature (8 and 9%, respectively, p<0.005)
compared with their parental cells.
To further investigate the apoptosis associated with oxidative
stress, we examined the apoptotic features in various cells with a
superoxide-generating drug, paraquat [43]. Cells were treated
with 250 μM paraquat for 48 h, and apoptosis analysis was
carried out. As shown in Fig. 8B, the Le1.3.1 cells displayed
more significant cell death (33% apoptosis, p<0.00001)
compared with the control 143B cells (8% apoptosis).
Interestingly, LeNDI1-1 and -2 cells exhibited much moreNDI1-1, -2 cells incubated for 6 h with 500 nM staurosporine (A), or 48 h with
lei of DAPI-stained cells. Percent of TUNEL-positive cells of 143B, Le1.3.1, and
t (D) were analyzed by visualizing labeled nick ends of DNA strands with the
pase-Glo 3/7 kit (Promega) after treatment with 500 nM staurosporine (E) and
ut, and the error bars indicate 2 times of the standard errors of the mean.
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respective, p<0.00001) compared with their parental cells.
These results suggested that complex I is an important target for
oxidative stress.
Since not all cells with shrunken nuclei are undergoing
apoptosis, we also carried out the TUNEL (terminal transferase
dUTP nick end labeling) assay, a common method for detecting
DNA fragmentation that results from apoptotic signaling
cascades. When treated with 500 nM staurosporine, more
Le1.3.1 cells which carried G11778A mutation were TUNEL-
positive (27%, p<0.05) compared with the control 143B cells
(5%), while less LeNDI1-1 and -2 cells exhibited such feature
(about 5%, p<0.005) compared with their parental cells (Fig.
8C). When oxidative stress was induced by 250 μM paraquat,
more Le1.3.1 cells were TUNEL-positive (30%, p<0.01)
compared with the control 143B cells (12%). Again, LeNDI1-
1 and -2 cells showed much more resistance to paraquat-
dependent cell death (6 and 2%, respective, p<0.05) compared
with their parental cells (Fig. 8D).
The apoptotic properties were further verified by caspase-
Glo 3/7 assay which measured the caspase-3 and -7 activities.
The assay provides a luminogenic caspase-3/7 substrate, which
contains the tetrapeptide sequence DEVD. Le1.3.1 cells treated
with 500 nM staurosporine exhibited 24% (p<0.05) increase in
caspase 3/7 activity while the NDI1 expression decrease the
activity in cells carrying G11778A by 24–25% (p<0.05) (Fig.
8E). When oxidative stress was induced by 250 μM paraquat,
caspase activity was increased by 3.5-fold (p<0.05) in Le1.3.1
cells, and the NDI1 reduced the activities by 62–81% (p<0.01)
in the transfectants (Fig. 8F).
All these results supported the notion that oxidative stress
mediated apoptosis might play a role in the pathogenesis of
LHON cells, and bypassing complex I will make the cells more
resistant to oxidative stress and cell death.
4. Discussion
In a previous paper, we reported that yeast NDI1 protein was
localized in the inner mitochondrial membrane and integrated
into the host respiratory chain after being introduced into a
human cell line lacking the functional complex I assembly [27].
In the present study, we extended the exploration of the
potential usefulness of the NDI1 gene as a therapeutic tool for
diseases involving complex I defect by delivering the yeast
NDI1 gene into a human cell line carrying an mtDNA mutation
which causes LHON.
There is a controversy on the complex I function associated
with G11778Amutation [44–47], probably due to the difference
in the origins of the mtDNA, the recipient rho zero cells, the way
to generate the cybrids and analytical methods. A partially active
complex I and a compromised oxidative phosphorylation
capability were recorded with the cybrids carrying the
G11778A mutation in this study, as reported by the group
where the mutation cells were obtained [20]. Interestingly, in the
NDI1 transformants carrying the G11778A mutation, both total
and the complex I-dependent respirations are largely resistant to
complex I inhibitor, rotenone. The complex I content, as shownby BNG analysis, was even higher in NDI1 transfected cells.
This result, to some extent, was probably due to the fact that
NDI1-type enzyme and complex I are known to coexist in plant
and fungal mitochondria and in bacteria [48]. Interestingly, a
previous study reported that the respiration is totally resistant to
rotenone while NDI1 gene was transfected in human embryonic
kidney 293 (HEK 293) cells [26]. The discrepancy might be due
to the difference in copy numbers of the transgene. Nevertheless,
all these results indicate that NDI1 serves as a better shuttle for
electrons between NADH and ubiquinone.
One of the surprising results of this study is that the complex
III activities were also shown to be reduced by enzymatic
assays. These effects could be mediated by the interaction
between NDI1 and other respiratory complexes. Accumulating
evidence has pointed to existing of direct interaction among
respiratory complexes and supercomplexes [49–51]. Further
studies are required to understand the underling mechanisms.
Despite the fact that respiration fully recovered to the level of
control 143B cells in NDI1 transformants, ATP production in
those cells, though increased substantially compared with their
parental Le1.3.1 cells, did not reach the level of 143B. This
could be due to the lack of the proton pumping translocating site
in NDI1 protein [21]. Nevertheless, both LeNDI1-1 and -2 cells
grew well in galactose medium where ATP generation
predominantly relies on mitochondria.
The important finding from this study is that NDI1 helps the
cells in carrying the G11778A mutation to reduce the oxidative
stress and to increase resistance to apoptosis, particularly the
apoptosis induced by oxidative stress. As suggested previously
[52,53], since complex I is one of the major sites for ROS
generation, bypassing the defective complex I by NDI1 would
decrease the oxidative stress. However, it was reported from a
previous study on ROS level in cell carrying G11778Amutation
that a significant increase in ROS was recorded only in the
differentiated neurons, but not in other cell types [54]. This
discrepancy could be attributed to the difference in the nuclear
background of the cybrids, and the variations could be
introduced in the process of creation of the mtDNA-less °ρ
cells and the selection of trans-mitochondrial cells. Our results
further demonstrated that by bypassing the electron transferring
through defective complex I, not only the production of ROS,
but the sensitivity to oxidative stress induced cell death has been
decreased. Complex I, thus, appears to be both the major
production and targeting site for ROS.
In a mouse model where ROS was increased as the result of
inhibition of an antioxidant enzyme, mitochondrial manganese
superoxide dismutase (MnSOD), a striking of the similarity of
optic neuropathy to the histopathology of LHON was observed
[55]. Over-production of ROS has been documented in cybrids
carrying all 3 LHON mutations [56]. Meanwhile, one of the
important molecular biology features of LHON is the
preferential cell death of the retinal ganglion cells and atrophy
of the optic nerve [17,42]. Cells carrying any one of the three
primary mutations (G11778A, G3460A and T14484C) have
been shown to undergo a caspase-independent apoptosis in
galactose medium [57,58], and cells carrying G11778A and
G3460A mutations have also been reported to be sensitized to
541J.S. Park et al. / Biochimica et Biophysica Acta 1772 (2007) 533–542Fas-induced apoptosis with an increased caspase 3 activity [59].
Here we showed that with the decreasing ROS production in the
NDI1 transformed cells, both the cell growth capacity in the
galactose medium and the resistance to cell death under
apoptotic induction and oxidative stress have been increased.
These results suggested that ROS might mediate the cell death
pathway in the LHON patients.
Yeast NDI1 gene has been introduced to more than 10 cell
lines [25–27,60–62], including nonproliferating cells, mouse
skeletal muscle, and substantia nigra. The results obtained in the
present work further provided strong evidence to support NDI1
as a tool to decrease the oxidative stress in the cells carrying a
pathogenic mutation. The utilization of NDI1 in the treatment of
neurodegenerative diseases caused by complex I defects
including LHON looks promising.
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